Comedian Aishwarya Mohanraj recently revealed that she used Mounjaro (tirzepatide) to manage weight after struggling for years despite strict diet and exercise. Her candid discussion has reignited conversations about obesity, its treatment, and the role of GLP-1 therapies in managing weight and blood sugar.
Obesity is increasingly recognized as a chronic metabolic disease, not just a cosmetic concern. Weight gain is influenced by a complex mix of hormones, genetics, metabolism, lifestyle, sleep, and stress. GLP-1 medications, like Mounjaro, mimic gut hormones that regulate appetite and blood sugar, helping individuals feel full sooner and consume fewer calories.
“GLP-1 therapies, when used appropriately, can be transformative,” says Dr. Arun Kumar, Consultant Endocrinologist and Metabolic Health Specialist. “But they are not suitable for everyone, and careful evaluation is essential before starting treatment.”
What Are GLP-1 Therapies?
GLP-1 (glucagon-like peptide-1) drugs act like natural gut hormones released after meals. These hormones:
- Control blood sugar levels
- Slow stomach emptying
- Signal the brain to reduce appetite
Medications such as semaglutide and tirzepatide (Mounjaro) have been shown to produce weight loss of over 10% when combined with lifestyle interventions. They also support improved blood sugar control and reduce metabolic risks in eligible patients.
Who Can Consider GLP-1 Injections?
GLP-1 therapies may be suitable for:
- Adults with a BMI ≥30 (obesity)
- Adults with BMI ≥27 who have weight-related conditions, such as type 2 diabetes, high blood pressure, sleep apnea, or high cholesterol
- Patients with type 2 diabetes who need improved glycemic control and weight reduction
- Individuals who have not achieved lasting weight loss with diet and exercise alone
Who Should Avoid GLP-1 Therapies?
GLP-1 injections are not recommended for:
- Individuals with personal or familial medullary thyroid cancer
- Those with Multiple Endocrine Neoplasia type 2 (MEN2)
- Patients with severe gastrointestinal conditions such as gastroparesis
- Pregnant or breastfeeding women
- People seeking purely cosmetic weight loss without a medical indication
These drugs require a prescription and medical supervision.
Pre-Treatment and Ongoing Care
Medical Evaluation: A detailed review of medical history, current medications, and lab tests is essential.
Side Effects: Common effects include nausea, vomiting, or diarrhea, which often improve within a few weeks.
Lifestyle Commitment: GLP-1 therapies are not magic bullets. Long-term success requires healthy eating and regular physical activity.
Routine Monitoring: Regular check-ups help track safety and effectiveness.
FAQs on Mounjaro for Weight Loss
Q: What is Mounjaro?
A: Mounjaro is a prescription injectable containing tirzepatide, initially approved for type 2 diabetes and now also for weight management in eligible individuals.
Q: How does Mounjaro support weight loss?
A: It works on GLP-1 and GIP hormones, regulating appetite, digestion, and blood sugar, reducing hunger and increasing fullness.
Q: Who is eligible to take Mounjaro?
A: Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related health conditions, under medical supervision.
Q: Is Mounjaro different from other GLP-1 drugs?
A: Yes. It targets two hormone pathways (GLP-1 and GIP), potentially enhancing effectiveness compared to single-hormone therapies.
Q: How is it administered?
A: Mounjaro is a once-weekly subcutaneous injection.
